Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

Japan­ese drug­mak­er Ky­owa Kirin is ac­quir­ing most of the com­mer­cial rights for Ku­ra On­col­o­gy’s tar­get­ed leukemia treat­ment, pay­ing $330 mil­lion up­front and al­most $1.2 bil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER